Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data
暂无分享,去创建一个
Jyrki Lötjönen | Lennart Thurfjell | Roger Lundqvist | Johan Lilja | Christopher C Rowe | Benjamin A Thomas | Victor L Villemagne | C. Rowe | L. Thurfjell | J. Lötjönen | V. Villemagne | B. Thomas | J. Lilja | R. Lundqvist
[1] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[2] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[3] M. J. D. Powell,et al. An efficient method for finding the minimum of a function of several variables without calculating derivatives , 1964, Comput. J..
[4] M. Modat,et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[5] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[7] C. Rowe,et al. Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.
[8] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[9] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[10] et al.,et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.
[11] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[12] A. Paetau,et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. , 2008, Brain : a journal of neurology.
[13] Lars Eriksson,et al. Transformations and algorithms in a computerized brain atlas , 1992 .
[14] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[15] Karl J. Friston,et al. Spatial transformation of images , 1997 .
[16] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[17] Guy Marchal,et al. Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.
[18] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[19] R. Koeppe,et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[21] Jörn Diedrichsen,et al. A spatially unbiased atlas template of the human cerebellum , 2006, NeuroImage.
[22] A. Dale,et al. Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.
[23] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[24] H. Gertz,et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[25] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[26] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[27] Karl J. Friston,et al. Human Brain Function , 1997 .